Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Nektar Therapeutics securities during the specified Class Period from February 26, 2025, to December 15, 2025, due to alleged misleading statements and failures to disclose critical information regarding the REZOLVE-AA trial [1][5]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false and/or misleading statements and failed to disclose that enrollment in the REZOLVE-AA trial did not follow applicable instructions and protocol standards [5]. - It is alleged that the integrity and prospects of the REZOLVE-AA trial were overstated, leading to significant negative impacts on the trial's results [5]. - Investors are said to have suffered damages when the true details about the trial were revealed to the market [5]. Group 2: Participation Information - Investors who purchased Nektar securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 5, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in this area [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Class A common stock of NuScale Power Corporation between May 13, 2025, and November 6, 2025, about the upcoming lead plaintiff deadline on April 20, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought NuScale Class A common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 20, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that NuScale Power Corporation made false or misleading statements regarding ENTRA1 Energy LLC's capabilities, claiming it had no significant experience in nuclear power generation [5]. - It is asserted that NuScale's commercialization strategy was exposed to undisclosed risks, including potential failures and regulatory challenges, which led to investor damages when the true information became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Franklin BSP Realty Trust, Inc. during the specified class period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Franklin BSP Realty securities between November 5, 2024, and February 11, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 27, 2026 [3]. - The lawsuit alleges that defendants made false and misleading statements regarding Franklin BSP Realty's prospects and ability to maintain its dividend, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements in securities class actions, including the largest settlement against a Chinese company and significant recoveries for investors in recent years [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Picard Medical, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Picard Medical securities between September 2, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 13, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Picard Medical's defendants made materially false and misleading statements and failed to disclose adverse facts about the company's operations and securities trading [5]. - Specific allegations include involvement in a fraudulent stock promotion scheme, insider trading through offshore accounts, and misleading public statements regarding the company's business prospects [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Paysafe Limited securities during the specified class period of the upcoming lead plaintiff deadline on April 7, 2026, and the potential for compensation through a contingency fee arrangement [1][2]. Group 1: Class Action Details - Investors who bought Paysafe securities between March 4, 2025, and November 12, 2025, may be eligible to join a class action lawsuit without upfront costs [1][2]. - A class action lawsuit has already been filed, and interested parties must act by the April 7, 2026, deadline to serve as lead plaintiff [2][5]. - The lawsuit alleges that Paysafe made misleading statements regarding its business operations and financial health, which led to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [3]. - Rosen Law Firm has consistently ranked among the top firms for securities class action settlements since 2013, showcasing its expertise and resources [3].

Group 1 - The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Barclays PLC due to allegations of materially misleading business information [1] - Investors who purchased Barclays securities may be entitled to compensation through a class action without any out-of-pocket fees [2] - Barclays has a reported exposure of £600 million (approximately $809.70 million) to the UK mortgage provider Market Financial Solutions Ltd, which has raised concerns about wider losses among banks [3] Group 2 - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Enphase Energy, Inc. securities between April 22, 2025, and October 28, 2025, of the April 20, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Enphase securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 20, 2026, to serve as lead plaintiff [2]. - The lawsuit alleges that Enphase made false and misleading statements regarding its inventory management and financial prospects, which led to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action settlements [3].

Core Viewpoint - A class action lawsuit has been filed against ODDITY Tech Ltd. for misleading statements regarding its business operations and financial prospects during the Class Period from February 26, 2025, to February 24, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that ODDITY's largest advertising partner's algorithm change led to advertisements being diverted to lower quality auctions, significantly increasing customer acquisition costs [5]. - Defendants allegedly overstated the strength and sustainability of ODDITY's digital operating model, resulting in materially false and misleading public statements [5]. - Investors reportedly suffered damages when the true details of the situation became public [5]. Group 2: Participation Information - Investors who purchased ODDITY securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by May 11, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing clients [4].

Core Viewpoint - A class action lawsuit has been filed against Eos Energy Enterprises, Inc. for alleged misleading statements and failures to disclose critical operational issues during the class period from November 5, 2025, to February 26, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Eos Energy was unable to meet its production and capacity utilization targets as previously guided [5]. - It is alleged that Eos Energy's battery line experienced downtime significantly above industry norms and internal forecasts [5]. - The company faced delays in achieving quality targets for its automated bipolar production, and its systems were inadequate for providing accurate guidance and timely disclosures [5]. Group 2: Investor Information - Investors who purchased Eos Energy securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must be appointed by May 5, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. for the period between June 16, 2025, and January 8, 2026, due to alleged misleading statements regarding the company's New Drug Application for Anaphylm [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Aquestive made false and/or misleading statements and failed to disclose the true state of its New Drug Application for Anaphylm, particularly regarding the human factors involved in the use of its sublingual film [5]. - Investors who purchased Aquestive securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 4, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].